Inhibitor development upon switching from plasma-derived to recombinant factor VIII in previously untreated patients with severe hemophilia A: the PUP-SWITCH study

Background: The SIPPET randomized clinical trial showed that in previously untreated patients (PUPs) with severe hemophilia A, treatment with plasma-derived factor (F)VIII (pdFVIII) within the first 50 exposure days (EDs) was associated with a lower cumulative incidence of inhibitors than with recom...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Syna Miri, Frits R. Rosendaal, Kaan Kavakli, Peyman Eshghi, Soha Mohammadi Moghaddam, Sara Scardo, Behnaz Habibpanah, Mohsen Elalfy, Susan Halimeh, Gabriella Nicolò, Dilek Gökçebay, Namık Özbek, Tiraje Celkan, Ahmad Mohammadi, Mehran Karimi, Amin Shahsavani, Bariş Yılmaz, Canan Albayrak, Burcak Gunes, Zühre Kaya, Yilmaz Ay, Sinan Akbayram, Nazan Sarper, Pier Mannuccio Mannucci, Flora Peyvandi
Format:	Artigo
Sprog:	Inglês
Udgivet:	Elsevier 2024-11-01
Serier:	Research and Practice in Thrombosis and Haemostasis
Fag:	factor VIII factor VIII/adverse events factor VIII/immunology factor VIII/therapeutic use hemophilia A/drug therapy
Online adgang:	http://www.sciencedirect.com/science/article/pii/S2475037924002905
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!